Epidermal growth factor receptor and glioblastoma multiforme:: molecular basis for a new approach

被引：23

作者：

Belda-Iniesta, Cristobal ^{[1
,2
]}

de Castro Carpeno, Javier ^{[1
]}

Sereno, Maria ^{[1
,2
]}

Gonzalez-Baron, Manuel ^{[1
,2
]}

Perona, Rosario ^{[3
]}

机构：

[1] Univ Autonoma Madrid, Univ Hosp La Paz, Div Med Oncol, Translat Oncol Unit,CSIC UAM, ES-28046 Madrid, Spain

[2] MD Anderson Canc Ctr Int, Div Med Oncol, Madrid, Spain

[3] Biomed Res Inst Alberto Sols, Translat Oncol Unit CSIC UAM, Madrid, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2008年 / 10卷 / 02期

关键词：

EGFr; gliomas; tyrosine kinase; PTEN; AKT;

D O I：

10.1007/s12094-008-0159-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High-grade gliomas are the most common primary malignant brain tumours. Surgery, radiotherapy and chemotherapy are the cornerstone of actual treatment. In spite of large therapeutic efforts, overall survival is still poor. New molecular data allow a new molecular classification for high-grade gliomas and open a therapeutic window for targeted therapy. Molecular diagnostic tools may provide a basis for receptor-based therapies and enough information to personalise future treatments. In this regard, epidermal growth factor receptor (EGFR) is a target that will play a critical role in the management of glioma patients. This review summarises basic and preclinical data that support future use of therapies against EGFR.

引用

页码：73 / 77

页数：5

共 25 条

[1] Epidermal growth factor receptor and Ink4a/Arf:: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis [J].

Bachoo, RM ;

Maher, EA ;

Ligon, KL ;

Sharpless, NE ;

Chan, SS ;

You, MJJ ;

Tang, Y ;

DeFrances, J ;

Stover, E ;

Weissleder, R ;

Rowitch, DH ;

Louis, DN ;

DePinho, RA .

CANCER CELL, 2002, 1 (03) :269-277

[2] Molecular biology of malignant gliomas [J].

Belda-Iniesta C. ;

Castro Carpeño J. ;

Sáenz E.C. ;

Guerrero P.C. ;

Perona R. ;

Barón M.G. .

Clinical and Translational Oncology, 2006, 8 (9) :635-641

[3]

Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.0.CO

[4]

2-B

[5] MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer [J].

Chattopadhyay, S. ;

Machado-Pinilla, R. ;

Manguan-Garcia, C. ;

Belda-Iniesta, C. ;

Moratilla, C. ;

Cejas, P. ;

Fresno-Vara, J. A. ;

de Castro-Carpeno, J. ;

Nistal, M. ;

Gonzalez-Baron, M. ;

Perona, R. .

ONCOGENE, 2006, 25 (23) :3335-3345

[6]

Frederick L, 2000, NEURO-ONCOLOGY, V2, P159, DOI 10.1093/neuonc/2.3.159

[7]

Frederick L, 2000, CANCER RES, V60, P1383

[8]

Goudar RK, 2005, MOL CANCER THER, V4, P101

[9] Transactivation of the epidermal growth factor receptor by formylpeptide receptor exacerbates the malignant behavior of human glioblastoma cells [J].

Huang, Jian ;

Hu, Jinyue ;

Bian, Xiuwu ;

Chen, Keqiang ;

Gong, Wanghua ;

Dunlop, Nancy M. ;

Howard, O. M. Zack ;

Wang, Ji Ming .

CANCER RESEARCH, 2007, 67 (12) :5906-5913

[10] Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma [J].

Huang, Paul H. ;

Mukasa, Akitake ;

Bonavia, Rudy ;

Flynn, Ryan A. ;

Brewer, Zachary E. ;

Cavenee, Webster K. ;

Furnari, Frank B. ;

White, Forest M. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (31) :12867-12872

← 1 2 3 →